COVID-19 Antiviral Therapies at Montefiore

If you are at high risk for severe illness from COVID-19, you may qualify for antiviral treatments, including oral antiviral treatments. Montefiore Medical Center will be offering prescriptions for Nirmatrelvir/Ritonavir (Paxlovid), Lagevrio (Molnupiravir), or appointments for IV Remdesivir as the most effective treatments against the current Omicron subvariants.

Speak with your healthcare provider about which therapy is most appropriate for you, or contact us at

IV Remdesivir

Starting early December 2022, patients presenting within seven days of symptoms who are at highest risk for severe COVID-19 due to moderate-to-severe immunocompromise, and who cannot receive oral antivirals, may be eligible for a three-day consecutive course of outpatient IV remdesivir at the Montefiore COVID-19 Outpatient Therapeutics Program at 1575 Blondell Avenue, Bronx, NY 10461. Treatment will be offered Monday – Friday. Patients must be willing to come to our infusion center for three consecutive days. Others will be offered oral antiviral medications if no contraindications.

For more information, please contact us at 718-405-8125 or

What are oral antiviral therapies against COVID-19?

There are two FDA-approved oral antivirals available, and these are Paxlovid and Molnupiravir. The first is preferred because of greater effectiveness against COVID-19. Unlike monoclonal antibodies, these agents can be taken at home. As with monoclonal antibodies, patients are eligible if they have recently developed COVID-19, have tested positive by PCR or antigen test, and have any high risk condition listed below. A prescription can be sent by your healthcare provider, or your provider can consult our program at the information listed below. You must be within five days of onset of your symptoms to qualify. 

Am I eligible for COVID therapies?

To qualify, you must have tested positive for COVID-19 recently (by antigen or PCR test); have mild to moderate symptoms that are managed without oxygen support; and fall into one of the high risk categories below. These treatments are not for patients who are hospitalized for COVID-19.

You're eligible if you have any ONE of the following:


  • Older Age (for example, 55-65 years and up)
  • Chronic heart disease
  • COPD/chronic respiratory disease, including moderate asthma or emphysema
  • Diabetes (Type 1 or Type 2) on chronic medications
  • Chronic kidney disease
  • Immunosuppression due to a chronic medical condition (for example, active cancer, HIV, organ transplant, and others)
  • You're taking medicine that weakens your immune system
  • Pregnant (or recently delivered)
  • Neurodevelopmental, genetic, or metabolic disorder like Cerebral Palsy
  • Member of a racial or ethnic minority group at increased risk for severe Covid-19
  • Sickle Cell Disease
  • Medical technology dependent (trach, feeding tube, etc.)


If you have any specific questions on COVID therapeutics for children, please reach out to the Pediatric Infectious Consult service at 718-741-2470.

How do I get access to COVID-19 Therapies?

To schedule an appointment, please call 718 405 8125.

Referral Process

Location and Contact Information

All patient referral requests must be sent to


1575 Blondell Ave, Suite 125, 2nd Floor
Bronx, NY 10461
Business Hours: Monday - Friday 8:30am - 5:00pm

Priya Nori, MD

Longstanding inequities and chronic disease have led to high COVID-19 infection rates and significant risk of death in the Bronx. Now Bronx residents have a safe, evidence-based treatment that stops COVID-19 in its tracks and is preventing severe illness.

Priya Nori, MD
Infectious disease specialist and Director of the Antibiotic Stewardship Program at Montefiore, and Associate Professor of Medicine at Albert Einstein College of Medicine

Trusted Information Resources

Centers for Disease Control and Prevention

The leading national public health institute of the United States

For the latest COVID-19 guidelines and information from New York State 

World Health Organization

UN agency responsible for international public health